elsevier conference - partnering activities?

starts tomorrow in US

http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos

Prana Biotechnology
http://www.pranabio.com/

PBT2 for Alheimer’s and Huntington’s Disease

Prana Biotechnology is developing a novel class of compounds for the treatment of neurodegenerative diseases including PBT2 for Alzheimer’s and Huntington’s diseases, and PBT434 for Parkinson’s disease. The hallmark of each of these diseases is the accumulation of misfolded proteins and the production of reactive oxygen species. The abnormal distribution of certain metal ions is believed to contribute to this pathology, and Prana’s compounds reduce the ability of metals to participate in these aberrant processes.

Prana is expecting two key clinical milestones in Q1 2014 – Phase II results of its lead compound, PBT2, in the IMAGINE trial for Alzheimer’s disease and Reach2HD trial in Huntington’s. An earlier trial of PBT2 in 78 mild Alzheimer patients showed statistically significant improvement in measures of executive function and reduced levels of Abeta42 in the CSF, a relevant biomarker.

Prana will initiate partnering activities for PBT2 when data from the current clinical trials is available, expected by the end of Q1 2014.

Prana Biotechnology was founded in Melbourne, Australia, in 1997. The Company listed on the Australian Stock Exchange (ASX:PBT) in 2000 and listed on the NASDAQ (PRAN) in 2002.